News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,781 Results
Type
Article (40961)
Company Profile (267)
Press Release (681543)
Multimedia
Podcasts (82)
Webinars (17)
Section
Business (204688)
Career Advice (2025)
Deals (35536)
Drug Delivery (114)
Drug Development (81394)
Employer Resources (173)
FDA (16419)
Job Trends (14947)
News (346436)
Policy (32734)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2573)
Accelerated approval (35)
Adcomms (24)
Allergies (149)
Alliances (49575)
ALS (174)
Alzheimer's disease (1680)
Antibody-drug conjugate (ADC) (321)
Approvals (16698)
Artificial intelligence (531)
Autoimmune disease (162)
Automation (43)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (194)
Biotechnology (174)
Bladder cancer (162)
Brain cancer (58)
Breast cancer (649)
Cancer (4918)
Cardiovascular disease (408)
Career advice (1711)
Career pathing (36)
CAR-T (285)
CDC (48)
Celiac Disease (2)
Cell therapy (753)
Cervical cancer (37)
Clinical research (69682)
Collaboration (1740)
Company closure (4)
Compensation (1182)
Complete response letters (57)
COVID-19 (2715)
CRISPR (94)
C-suite (875)
Cystic fibrosis (143)
Data (6373)
Decentralized trials (2)
Denatured (25)
Depression (136)
Diabetes (507)
Diagnostics (6724)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (257)
Drug pricing (187)
Drug shortages (28)
Duchenne muscular dystrophy (237)
Earnings (90334)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117605)
Executive appointments (988)
FDA (19605)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1499)
Gene editing (201)
Generative AI (44)
Gene therapy (605)
GLP-1 (974)
Government (4670)
Grass and pollen (6)
Guidances (385)
Healthcare (18884)
HIV (62)
Huntington's disease (47)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (63)
Indications (125)
Infectious disease (2996)
Inflammatory bowel disease (195)
Inflation Reduction Act (14)
Influenza (120)
Intellectual property (256)
Interviews (316)
IPO (16644)
IRA (50)
Job creations (3643)
Job search strategy (1428)
JPM (57)
Kidney cancer (17)
Labor market (86)
Layoffs (547)
Leadership (33)
Legal (7951)
Liver cancer (92)
Longevity (17)
Lung cancer (663)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (822)
MASH (165)
Medical device (13788)
Medtech (13848)
Mergers & acquisitions (19971)
Metabolic disorders (1287)
mRNA (158)
Multiple sclerosis (166)
NASH (16)
Neurodegenerative disease (326)
Neuropsychiatric disorders (89)
Neuroscience (2943)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4515)
Now hiring (68)
Obesity (606)
Opinion (264)
Ovarian cancer (168)
Pain (202)
Pancreatic cancer (234)
Parkinson's disease (288)
Partnered (33)
Patents (512)
Patient recruitment (510)
Peanut (59)
People (58953)
Pharmaceutical (62)
Pharmacy benefit managers (30)
Phase 1 (21724)
Phase 2 (30669)
Phase 3 (22845)
Pipeline (5626)
Policy (290)
Postmarket research (2564)
Preclinical (9211)
Press Release (64)
Prostate cancer (250)
Psychedelics (48)
Radiopharmaceuticals (289)
Rare diseases (866)
Real estate (5956)
Recruiting (70)
Regulatory (24599)
Reports (53)
Research institute (2393)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (150)
Series A (248)
Series B (191)
Service/supplier (11)
Sickle cell disease (100)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3617)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (84)
The Weekly (55)
Vaccines (1014)
Venture capital (89)
Weight loss (386)
Women's health (96)
Worklife (18)
Date
Today (177)
Last 7 days (722)
Last 30 days (2676)
Last 365 days (29947)
2026 (4508)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54084)
2019 (46538)
2018 (35019)
2017 (32108)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (86)
Alaska (7)
Arizona (313)
Arkansas (13)
Asia (39256)
Australia (6419)
California (11525)
Canada (3336)
China (1113)
Colorado (483)
Connecticut (487)
Delaware (341)
Europe (84679)
Florida (1729)
Georgia (364)
Hawaii (3)
Idaho (61)
Illinois (884)
India (70)
Indiana (533)
Iowa (22)
Japan (439)
Kansas (127)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1405)
Massachusetts (8239)
Michigan (331)
Minnesota (632)
Mississippi (5)
Missouri (129)
Montana (32)
Nebraska (28)
Nevada (124)
New Hampshire (80)
New Jersey (3057)
New Mexico (28)
New York (3032)
North Carolina (1475)
North Dakota (8)
Northern California (5657)
Ohio (343)
Oklahoma (21)
Oregon (41)
Pennsylvania (2330)
Puerto Rico (24)
Rhode Island (49)
South America (1108)
South Carolina (68)
South Dakota (1)
Southern California (4489)
Tennessee (178)
Texas (1773)
United States (40805)
Utah (348)
Vermont (1)
Virginia (268)
Washington D.C. (81)
Washington State (932)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
722,781 Results for "scynexis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
January 21, 2026
·
6 min read
Press Releases
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
November 20, 2025
·
2 min read
Press Releases
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
December 23, 2025
·
3 min read
Press Releases
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
November 18, 2025
·
5 min read
Press Releases
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 6, 2025
·
10 min read
Press Releases
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
January 29, 2026
·
3 min read
Press Releases
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
October 16, 2025
·
3 min read
Press Releases
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
·
10 min read
Press Releases
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
August 25, 2025
·
1 min read
Press Releases
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
October 1, 2025
·
4 min read
1 of 72,279
Next
